Amendments to the Claims

1- 6. (Canceled)

7. (Withdrawn – Currently Amended) A method of treating a condition in a mammal, the treatment of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound selected from the group consisting of 7-methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride; 2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one; and 3-cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione ~~of Claim 1~~ in an amount that is effective at inhibiting $K_V1.5$.

8. (Withdrawn) A method of Claim 7, wherein the condition is cardiac arrythmia.

9. (Withdrawn) A method of Claim 8, wherein the cardiac arrythmia is atrial fibrillation.

10. (Withdrawn) A method of Claim 8, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

11. (Withdrawn- Currently Amended) A method of preventing a condition in a mammal, the prevention of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound selected from the group consisting of 7-methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride; 2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one; and 3-cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione ~~of Claim 1~~ in an amount that is effective at inhibiting $K_V1.5$.

12. (Withdrawn) A method of Claim 11, wherein the condition is cardiac arrythmia.

13. (Withdrawn) A method of Claim 12, wherein the cardiac arrythmia is atrial fibrillation.

14. (Withdrawn) A method of Claim 12, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

15. (Withdrawn) A method of Claim 11, wherein the condition is a thromboembolic event.

16. (Withdrawn) A method of Claim 15, wherein the thromboembolic event is a stroke.

17. (Withdrawn) A method of Claim 11, wherein the condition is congestive heart failure.

18-20 (Canceled)

20. (Withdrawn- Currently Amended) A method of treating cardiac arrythmia comprising administering a compound of Claim ~~1~~ 7 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.

21. (Withdrawn –Currently Amended) A method for inducing a condition of normal sinus rhythm in a patient having atrial fibrillation, which comprises treating the patient with a compound of Claim ~~1~~ 7.

22. (Withdrawn- Currently Amended) A method for treating tachycardia in a patient which comprises treating the patient with an antitachycardia device in combination with a compound of Claim ~~1~~ 7.

23. (Currently Amended) A compound ~~having the formula~~



~~wherein~~

~~or a pharmaceutically acceptable salt thereof, wherein~~

~~z is a single or double bond;~~

~~A is an aryl ring, wherein any stable aryl ring atom is independently unsubstituted or substituted with~~

~~1) halogen,~~
~~2) NO_2;~~
~~3) CN,~~
~~4) $CR^{46}=C(R^{47}R^{48})_2$,~~
~~5) C≡C R^{46},~~
~~6) $(CR^iR^j)_rOR^{46}$,~~
~~7) $(CR^iR^j)_rN(R^{46}R^{47})$,~~
~~8) $(CR^iR^j)_r C(O)R^{46}$,~~
~~9) $(CR^iR^j)_r C(O)OR^{46}$,~~
~~10) $(CR^iR^j)_rR^{46}$,~~
~~11) $(CR^iR^j)_r S(O)_{0-2}R^{61}$,~~
~~12) $(CR^iR^j)_r S(O)_{0-2}N(R^{46}R^{47})$,~~
~~13) $OS(O)_{0-2}R^{61}$,~~
~~14) $N(R^{46})C(O)R^{47}$,~~
~~15) $N(R^{46})S(O)_{0-2}R^{61}$,~~
~~16) $(CR^iR^j)_rN(R^{46})R^{61}$,~~
~~17) $(CR^iR^j)_rN(R^{46})R^{61}OR^{47}$,~~
~~18) $(CR^iR^j)_rN(R^{46})(CR^kR^l)_sC(O)N(R^{47}R^{48})$,~~
~~19) $N(R^{46})(CR^iR^j)_rR^{61}$,~~
~~20) $N(R^{46})(CR^iR^j)_rN(R^{47}R^{48})$,~~
~~21) $(CR^iR^j)_rC(O)N(R^{47}R^{48})$, or~~
~~22) oxo,~~

~~R^2, R^8, R^9 and R^{10} are independently selected from:~~

1) hydrogen,

2) halogen,

3) NO_2,

4) CN,

5) $CR^{43}=C(R^{44}R^{45})$,

6) $C\equiv CR^{43}$,

7) $(CR^eR^f)_pOR^{43}$,

8) $(CR^eR^f)_pN(R^{43}R^{44})$,

9) $(CR^eR^f)_pC(O)R^{43}$,

10) $(CR^eR^f)_pC(O)OR^{43}$,

11) $(CR^eR^f)_pR^{43}$,

12) $(CR^eR^f)_pS(O)_{0-2}R^{60}$,

13) $(CR^eR^f)_pS(O)_{0-2}N(R^{43}R^{44})$,

14) $OS(O)_{0-2}R^{60}$,

15) $N(R^{43})C(O)R^{44}$,

16) $N(R^{43})S(O)_{0-2}R^{60}$,

17) $(CR^eR^f)_pN(R^{43})R^{60}$,

18) $(CR^eR^f)_pN(R^{43})R^{60}OR^{44}$,

19) $(CR^eR^f)_pN(R^{43})(CR^gR^h)_qC(O)N(R^{44}R^{45})$,

20) $N(R^{43})(CR^eR^f)_pR^{60}$,

21) $N(R^{43})(CR^eR^f)_pN(R^{44}R^{45})$, and

22) $(CR^eR^f)_pC(O)N(R^{43}R^{44})$,

or R^2 and R^8 are independently as defined above, and R^9 and R^{10}, together with the atoms to which they are attached, form the ring

, where R^m is C_{1-6}alkyl;

R^1 is selected from the group consisting of

1) hydrogen,

2) $(CR^aR^b)_nR^{40}$

3) $(CR^aR^b)_nOR^{40}$,

4) $(CR^aR^b)_nN(R^{40}R^{41})$,

5) $(CR^aR^b)_nN(R^{40})C(O)OR^{41}$,

6) $(CR^aR^b)_nN(R^{40})(CR^cR^d)_2N(R^{41})C(O)R^{49}$,

7) C_{3-8}-cycloalkyl,

8) $(CR^aR^b)_nC(O)OR^{40}$,

9) $(CR^aR^b)_nN(R^{40})(CR^eR^d)_{1-3}R^{41}$,

10) $(CR^aR^b)_nS(O)_{0-2}R^6$,

11) $(CR^aR^b)_nS(O)_{0-2}N(R^{40}R^{41})$,

12) $(CR^aR^b)_nN(R^{40})R^6OR^{41}$,

13) $(CR^aR^b)_nN(R^{40})(CR^eR^d)_{0-6}C(O)N(R^{41}R^{42})$;

or R^1 is absent when z is a double bond

R^5 is selected from the group consisting of

1) C_{1-6} alkyl,

2) =O

3) aryl

4) C_{3-10} cycloalkyl

5) C_{1-6}alkylene-$C(O)R^{11}$,

6) C_{1-6}alkylene-$C(O)R^{13}$

7) $C(O)R^{11}$,

8) $C(O)R^{13}$,

9) $C(O)OR^{11}$,

10) $C(O)OR^{13}$,

11) $C(O)N(R^{11}R^{11})$,

12) $C(O)N(R^{13}R^{13})$,

13) $C(O)N(R^{11}R^{13})$,

14) CN,

15) $NHC(O)R^{11}$,

16) $NHC(O)CF_3$, and

17) $NHC(O)C_{2-6}$alkyl;

R^{11} is selected from the group consisting of

1) aryl, and

2) an unsubstituted or substituted heterocyclic ring consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S; and

R^{13} is selected from the group consisting of

1) C_{1-6}alkyl,

2) C_{1-6}alkyloxy,

3) C_{1-6}alkenyl,

4) C_{1-6}alkynyl, and

5) CF_3;

R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, R^i, R^j, R^k, and R^l are independently selected from the group consisting of:

1) hydrogen,

2) C_1-C_6 alkyl,

3) halogen,

4) aryl,

5) R^{80},

6) C_3-C_{10} cycloalkyl, and

7) OR^4;

said alkyl, aryl, and cycloalkyl being unsubstituted, monosubstituted with R^7, disubstituted with R^7 and R^{15}, trisubstituted with R^7, R^{15} and R^{16}, or tetrasubstituted with R^7, R^{15}, R^{16} and R^{17};

R^4, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{51}, and R^{52} are independently selected from:

1) hydrogen,

2) C_1-C_6 alkyl,

3) C_3-C_{10} cycloalkyl,

4) aryl,

5) R^{81},

6) CF_3,

7) C_2-C_6 alkenyl, and

8) C_2-C_6 alkynyl,

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{18}, di-substituted with R^{18} and R^{19}, tri-substituted with R^{18}, R^{19} and R^{20}, or tetra-substituted with R^{18}, R^{19}, R^{20} and R^{21};

R^6, R^{60}, R^{61}, and R^{63} are independently selected from:

1) C_1-C_6 alkyl,

2) aryl,

3) R^{83}, and

4) C_3-C_{10} cycloalkyl;

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{26}, di-substituted with R^{26} and R^{27}, tri-substituted with R^{26}, R^{27} and R^{28}, or tetra-substituted with R^{26}, R^{27}, R^{28} and R^{29};

~~R^7, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{26}, R^{27}, R^{28}, and R^{29} are independently selected from:~~

~~1) C_1-C_6 alkyl,~~

~~2) halogen,~~

~~3) OR^{51},~~

~~4) CF_3,~~

~~5) aryl,~~

~~6) C_3-C_{10} cycloalkyl,~~

~~7) R^{84},~~

~~8) $S(O)_{0-2}N(R^{51}R^{52})$,~~

~~9) $C(O)OR^{51}$,~~

~~10) $C(O)R^{51}$,~~

~~11) CN,~~

~~12) $C(O)N(R^{51}R^{52})$,~~

~~13) $N(R^{51})C(O)R^{52}$,~~

~~14) $S(O)_{0-2}R^{63}$,~~

~~15) NO_2, and~~

~~16) $N(R^{51}R^{52})$;~~

~~R^{80}, R^{81}, R^{83} and R^{84} are independently selected from a group of unsubstituted or substituted heterocyclic rings consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S; and n, p, q, r, and s are independently 0, 1, 2, 3, 4, 5 or 6, provided that, when R^9 is hydrogen, A is substituted as defined above;~~

~~and wherein said compound is~~ selected from the group consisting of 7-methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one; 7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride; 2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one; 2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one; and 3-Cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione.

Claim 24 (Previously presented) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound of Claim 23 or a pharmaceutically acceptable crystal form or hydrate thereof.